MoonLake Shares Rise After FDA Grants Fast Track for SLK in Palmoplantar Pustulosis
MoonLake Immunotherapeutics saw its shares jump in premarket trading after the FDA awarded Fast Track designation to sonelokimab (SLK) for moderate-to-severe palmoplantar pustulosis (PPP). The decision comes on the heels of positive Phase 2 LEDA results and recent FDA guidance that supports the company’s planned Biologic License Application (BLA) s…